Burkina Faso

in page functions
[French]
Burkina Faso
Total population (2018) 19,724,347
Birth cohort (2018) 754,348
Surviving Infants (surviving to 1 year per year, 2018) 710,934
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 61/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 89/1000
World Bank Index, IDA (2015) 3.61
Gross Nation Income (per capita US$, 2015) 640
Co-financing group (2018) Initial self-financing
No. of districts/territories (2017) 70

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Burkina Faso

Type of support

Approvals

2001-2023 (US$)
(28 Nov 2018)

Commitments

2001-2023 (US$)
(28 Nov 2018)

Disbursements

2000-2018 (US$)
(28 Nov 2018)

% Disbursed

(28 Nov 2018)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $235,639,609 $260,417,109 $214,012,696
Cash Support (CASHSUPP) $145,000 $170,000 $145,000 100%
Cold Chain Equipment Optimisation Platform (CCEOP) $3,802,899 $3,802,899
Health system strengthening (HSS 1) $4,978,500 $4,978,500 $4,978,500 100%
Health system strengthening (HSS 2) $4,436,347 $4,436,347 $4,436,347 100%
Health system strengthening (HSS 3) $5,040,000 $11,760,000 $2,800,000 56%
HPV Demo (NVS) $189,506 $189,506 $190,622 101%
Immunisation services support (ISS) $9,705,605 $9,705,605 $9,705,605 100%
Injection Safety Devices (NVS) $1,003,479 $1,295,979 $620,700 62%
Injection safety support (INS) $931,560 $931,560 $931,560 100%
IPV (NVS) $2,712,179 $2,712,179 $842,072 31%
Measles (NVS) $1,247,229 $1,247,229 $1,234,922 99%
Measles-Rubella (NVS) $6,000,965 $6,000,965 $6,000,965 100%
Meningitis A (NVS) $1,548,371 $2,078,871 $987,159 64%
Meningitis A - mini catch-up campaign (NVS) $3,134,671 $3,134,671 $3,134,671 100%
Meningitis A - mini catch-up op.costs (OPC) $2,571,802 $2,571,802 $2,571,802 100%
MR - Operational costs (OPC) $4,925,847 $4,925,847 $4,925,847 100%
Penta (NVS) $65,397,939 $66,689,939 $64,359,150 98%
Pneumo (NVS) $63,045,663 $70,665,663 $63,403,779 101%
Product Switch Grant (PSG) $194,286 $194,286 $194,285 100%
Rotavirus (NVS) $51,069,267 $59,366,767 $38,991,216 76%
Vaccine Introduction Grant (VIG) $3,558,494 $3,558,494 $3,558,494 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Burkina Faso DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 91%
M:F sex ratio at birth (2018) 1.05
Household survey: DTP3 coverage for male (2009) 90.30%
Household survey: DTP3 coverage for female (2009) 88.80%
Household survey: Last DTP3 survey (2009) 90%
% districts achieving > 80% DTP3 coverage (2017) 99%
% districts achieving < 50% DTP3 coverage (2017) 0%
MCV WHO/UNICEF estimates (2017) 88%

Breakdown of support

Non-vaccine support Vaccine support
16% 84%
$34,247,440 $179,765,256

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Burkina Faso

31 July 2018

INFUSE workshop

Fingerprint records and digital health cards to help solve global identity crisis

Four companies will receive Gavi support to help scale emerging digital identification technologies in developing countries.

25 April 2017

Central African Republic, a mother and her two children.

Central African Republic: mother spreads word about meningitis A vaccine

Izimili Raude knows that her community must rely on vaccines, not miracles, to spare children from a deadly disease.

27 July 2016

First Sudanese child to receive Meningitis A vaccine as part of routine immunization.

Sudan: first to introduce life-saving meningitis A vaccine into routine immunization

Children in Sudan are set to become the first in the Meningitis belt to benefit from the introduction of Meningitis A vaccine into a routine immunization programme.

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

close icon

modal window here